RankAlpha logo
Back to Rankings

CING

CingulateC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Patent issuance plus successful manufacturing scale-up and favorable commercial data/partnerships drive re-rating toward higher analyst targets; scenario assumes commercial optionality materializes and interest from specialty pharma/partners.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Clinical/regulatory setbacks for CTx-1301
Momentum
12
Value
41
Sentiment
100
Setup hits (3d)
— · Net —
AI TargetsBase $9.50 · Bull $17.00 · Bear $4.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-10 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net —
Target $23.00
Why
Momentum12 · Δ7d -11.4
Value41 · Δ7d -0.1
Sentiment100 · Δ7d 0.0
So what
Balanced signals. Wait for confirmation before sizing up.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Sentiment · See AI snapshot
Momentum
12
26% active weight
Current posture
7d trendImproving
Δ7d
-11.4
Δ21d
-8.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
100
34% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade

Composite grade C. Momentum 12.3 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$61.15M
Beta
-0.77
Shares Out
13.47M
P/E (TTM) · Derived
-1.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.46
Rev YoY
-
EPS YoY
-9.7%
Gross Margin
-
Op Margin
-
Net Debt
-$2.17M
Current Ratio
2.55
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology